Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

asthma, lungs The combination therapy significantly reduced the risk of severe exacerbations and improved lung function. Topline results were announced from two phase 3 studies evaluating a fixed-dose ...

WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid ...

Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...

As-needed albuterol-budesonide (Airsupra) more effectively improved lung function in moderate-to-severe asthma than as-needed albuterol only, according to research presented at the CHEST annual ...

Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials PT027 significantly reduced the risk of severe ...

DALLAS — Single combination inhaler treatment with budesonide-formoterol on an as-needed basis, compared with albuterol, more than halved the risk for severe asthma attacks in patients with mild ...

LOUISVILLE, Ky. -- An investigational fixed-dose combination of a short-acting beta 2-adrenergic agonist and an inhaled corticosteroid appeared to slow the deterioration in lung function and reduce ...

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis AstraZeneca’s inhaled anti-inflammatory rescue medication AIRSUPRA demonstrated ...

AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma.1 The BATURA Phase IIIb trial, which evaluated severe exacerbation ...

The inclusion of BATURA study results in the US prescribing information builds upon the previous MANDALA Phase III trial in adult patients with moderate to severe asthma. 3 The MANDALA and BATURA ...